Given the intricate etiology and pathogenesis of atopic dermatitis (AD), the complete cure of AD remains challenging. This study aimed to investigate if topically applying N-benzyl-N-methyldecan-1-amine (BMDA), derived from garlic, and its derivative [decyl-(4-methoxy-benzyl)-methyl-1-amine] (DMMA) could effectively alleviate AD-like skin lesions in 2,4-dinitrochlorobenzene (DNCB)-treated mice. Administering these compounds to the irritated skin of DNCB-treated mice significantly reduced swelling, rash, and excoriation severity, alongside a corresponding decrease in inflamed epidermis and dermis. Moreover, they inhibited spleen and lymph node enlargement and showed fewer infiltrated mast cells in the epidermis and dermis through toluidine-blue staining. Additionally, they led to a lower IgE titer in mouse sera as determined by ELISA, compared to vehicle treatment. Analyzing skin tissue from the mice revealed decreased transcript levels of inflammatory cytokines (TNF-α, IL-1β, and IL-6), IL-4, iNOS, and COX-2, compared to control mice. Simultaneously, the compounds impeded the activation of inflammation-related signaling molecules such as JNK, p38 MAPK, and NF-κB in the mouse skin. In summary, these findings suggest that BMDA and DMMA hold the potential to be developed as a novel treatment for healing inflammatory AD.

鉴于特应性皮炎（AD）复杂的病因和发病机制，彻底治愈 AD 仍然具有挑战性。本研究旨在探讨是否局部使用源自大蒜的 N-苄基-N-甲基癸-1-胺 (BMDA) 及其衍生物[癸基-(4-甲氧基-苄基)-甲基-1-胺] (DMMA)可以有效缓解 2,4-二硝基氯苯 (DNCB) 治疗小鼠的 AD 样皮肤损伤。将这些化合物施用到 DNCB 处理的小鼠受刺激的皮肤上，可显着减轻肿胀、皮疹和表皮脱落的严重程度，同时表皮和真皮发炎的情况也相应减少。此外，它们抑制了脾脏和淋巴结肿大，并通过甲苯胺蓝染色显示表皮和真皮中浸润的肥大细胞较少。此外，与媒介物处理相比，通过 ELISA 测定，它们导致小鼠血清中 IgE 滴度较低。对小鼠皮肤组织的分析显示，与对照小鼠相比，炎症细胞因子（TNF-α、IL-1β 和 IL-6）、IL-4、iNOS 和 COX-2 的转录水平降低。同时，这些化合物阻碍了小鼠皮肤中 JNK、p38 MAPK 和 NF-κB 等炎症相关信号分子的激活。总之，这些发现表明 BMDA 和 DMMA 有潜力被开发为治疗炎症性 AD 的新疗法。